| Literature DB >> 31191433 |
Cecilia Rönnbäck1,2, Elisabeth Hansson3.
Abstract
Systemic low-grade inflammation can be initiated in vivo after traumatic injury or in chronic diseases such as neurodegenerative, metabolic, and autoimmune diseases. Inducers of inflammation trigger production of inflammatory mediators, which alter the functionality of tissues and organs and leads to harmful induction of different barrier systems in the body, where the blood-brain barrier, the blood-retinal barrier, blood-nerve barrier, blood-lymph barrier and the blood-cerebrospinal fluid barrier play major roles. The different barriers are unique but structured in a similar way. They are equipped with sophisticated junctional complexes where different connexins, protein subunits of gap junction channels and hemichannels, constitute important partners. The cells involved in the various barriers are coupled in networks, are excitable but do not express action potentials and may be targets for inflammation leading to changes in several biochemical cellular parameters. During any type of inflammation barrier break-down is observed where any form of injury can start with low-grade inflammation and may lead to systemic inflammation.Entities:
Keywords: blood-brain barrier; blood-cerebrospinal fluid barrier; blood-lymph barrier; blood-nerve barrier; blood-retinal barrier; low-grade inflammation; systemic inflammation
Year: 2019 PMID: 31191433 PMCID: PMC6549124 DOI: 10.3389/fneur.2019.00533
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Schematic illustration high-lightening different barriers in the body; the blood-brain barrier, blood-retinal barrier, blood-nerve barrier, blood-lymph barrier, and blood-cerebrospinal fluid barrier. The left side demonstrates the normal physiological conditions and the right side demonstrates inflammatory conditions. The illustration is made by Pontus Andersson, ArtProduction, Gothenburg, Sweden.
Characteristics for the blood-brain barrier, blood-retinal barrier, blood-nerve barrier, blood-lymph barrier and blood-cerebrospinal fluid barrier in physiological and inflammatory conditions.
| Cells and organelles: | Capillary endothelial cells, pericytes, perivascular endfeet of astrocytes, basal lamina, microglia, neuronal processes. Tight junctions between the endothelial cells ( |
| Inflammatory changes: | Tight junction alterations, upregulation of GLUT1 transporter, increase of inflammatory mediators; histamine, bradykinin, 5-HT, glutamate, purines, cytokines, growth factors, complement-derived polypeptides, free radicals, NO, lipids etc., ( |
| Barrier breakdown at pathological disorders: | Infectious or inflammatory processes; autoimmune diseases, MS, EAE, NMO; trauma; epilepsy; Parkinson's disease; neurodegenerative diseases, etc. see ( |
| Cells and organelles: | Retina vessel endothelial cells, astrocyte endfeet, Müller glial cells, pericytes, smooth muscle cells. Tight and gap junctions between endothelial cells ( |
| Inflammatory changes: | Tight junction alterations, transendothelial transport, changes of cells taking part in the barrier ( |
| Barrier breakdown at pathological disorders: | Macular edema, hyperglycemia, diabetic retinopathy, oxidative stress ( |
| Cells and organelles: | Retinal pigment epithelial cells. Tight, adherens and gap junctions between the epithelial cells, Bruch's membrane, choriocapillaris ( |
| Inflammatory changes: | Tight, adherens and gap junction alterations |
| Barrier breakdown at pathological disorders: | AMD ( |
| Cells and organelles: | Cubodial choroid plexus epithelial cells. Tight, adherens and gap junctions between the epithelial cells ( |
| Inflammatory changes: | Tight, adherens and gap junction alterations ( |
| Barrier breakdown at pathological disorders: | Neurodegenerative diseases, cerebral amyloid angiopathy, ischemia, tumors, HIV ( |
| Cells and organelles: | Endothelial cells, endoneural space, schwann cells, fibroblasts collagen fibrils. Tight junctions between endothelial cells ( |
| Inflammatory changes: | Tight junction alterations ( |
| Barrier breakdown at pathological disorders: | Diabetic neuropathy, lead neuropathy ( |
| Cells and organelles: | Lymphatic endothelial cells, basal lamina. Tight junctions between the endothelial cells [( |
| Inflammatory changes: | Tight junction alterations ( |
| Barrier breakdown at pathological disorders: | Inflammation, obesity, metabolic syndrome, inflammatory bowel disease ( |
NO, nitric oxide; MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; NMO, neuromyelitis optica; AMD, age-related macular degeneration.